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We studied recanalization of an obstructed left circumflex coronary artery by 
streptokinase in open-chest anesthetized dogs. Thrombotic occlusion was induced by a 
100 pA anodal current selectively delivered to the intimal surface of the vessel. 
Intracoronary streptokinase (50,tMO U) or saline was infused over a SO-min period 
beginning at either 30 min or !I0 min after occlusion. Continuous recordings were 
made of antegrade circumflex flow and regional myocardial function, which was 
quantitated using sonomicrometer crystals in the regions of the left anterior descend- 
ing and circumflex coronary arteries. In some experiments a fixed stenosis, having no 
effect on mean circumflex coronary artery blood flow, was placed at the site of 
subsequent thrombus formation. The presence of a stenosis decreased the weight of 
occlusive thrombi obtained from nonreperfused saline controls by 40% and increased 
the proportion of animals successfully reperfused by streptokinase from 13 to 76%. 
Streptokinase reduced thrombus mass by 44% in animals recanalized in the presence 
of the stenosis. On the average, reflow was established after 26 min of streptokinase 
infusion, was less in magnitude than pre-occlusion flow, and was unstable and 
intermittent, being marked by frequent reocchtsions. Initiating treatment at 30 min or 
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90 min post-occlusion did not influence characteristics of the reflow. Return of 
myocardial contractility in the ischemic bed was not detected during the immediate 
reperfusion period in the majority of these experiments. 
(Key words: streptokinase; myocardial reperfusion; coronary stenosis) 
Introduction 
A number of recent clinical studies [l-3] have affirmed the effectiveness of 
streptokinase (STK) in reestablishing antegrade flow in acutely thrombosed coronary 
vessels. Nevertheless, several aspects of STK induced recanalization of both basic 
and applied scientific interest have proved difficult to approach experimentally in 
humans.’ The size of the thrombus removed during STK infusion is uncertain, as is 
the pattern and extent of antegrade flow return. Estimation of the duration and 
degree of occlusion, which are important factors to consider when assessing changes 
in myocardial function, are also inherently imprecise. 
We have attempted to better delineate STK recanalization under carefully con- 
trolled conditions during acute thrombosis of canine coronary arteries in vivo. The 
model chosen employs a d.c. anodal current to selectively injure the intimal surface 
of the proximal left circumflex coronary artery (LCCA). The occlusive thrombi 
resulting from the intimal damage possess a morphology typical of arterial thrombi, 
a well-defined weight range and a susceptibility to inhibition by a variety of 
antiplatelet drugs [4,5]. This experimental model coupled with continuous monitor- 
ing of LCCA flow and regional LV function was used to determine the effectiveness 
of intracoronary STK in the absence and presence of a fixed stenosis. 
Materials and Methods 
Surgical preparation 
Male, mongrel dogs (17-21 kg) were anesthetized with sodium pentobarbital (30 
mg/kg, i.v.) and ventilated under positive pressure with room air using a Harvard 
respirator pump. All surgical procedures were performed by cauterization and blunt 
dissection to minimize bleeding during the subsequent administration of STK. 
Catheters were inserted into the carotid artery to record arterial pressure with a 
Statham P23DC pressure transducer and into the jugular vein for anesthetic supple- 
mentation. A left thoracotomy was performed at the 5th intercostal space and the 
heart was suspended in a pericardial cradle. A l-2 cm section of the left circumflex 
coronary artery (LCCA) was isolated proximal to the obtuse diagonal branch and 
instrumented with an infusion cannula, a calibrated electromagnetic flow probe 
(Carolina Electronics, 3 or 3.5 mm i.d.) a stimulation electrode and a teflon screw 
occluder (Fig. 1). The stimulation electrode consisted of a 25-gauge hypodermic 
needle tip (3-4 mm) attached to a 30-gauge teflon-coated, silver-plated copper wire. 




sonomicrometer crystal pairs 
Fig. 1. Surgical preparation for thrombolysis studies. The proximal LCCA was dissected free and the 
following were affixed to the vessel as illustrated: infusion cannula, electromagnetic flow probe, 
stimulation electrode and screw occluder. Sonomicrometer crystal pairs placed to a midwall depth as 
described in Materials and Methods. 
tip attached to Tygon tubing. The distance between the stimulation electrode and 
infusion cannula ranged from 2 to 8 mm; any intervening small LCCA branches 
were ligated. 
Fig. 1 illustrates the positioning of the piezoelectric crystals (Norland Instru- 
ments, 3 mm diameter) which were placed 10 to 15 mm apart at a midmyocardial 
depth of 6 mm in the myocardial regions subserved by the left anterior descending 
(LAD) and LCCA. The dimension gauge crystals were connected to an oscilloscope 
sonomicrometer (Norland, NI-202) and were operated in radial mode at 800 kHz, 
achieving a resolution of 0.05 @. The distance between each crystal pair (regional 
segment length) was quantitated by multiplying the transit time (pS) by the velocity 
of sound in myocardial tissue (1.58 mm/@). 
Continuous recordings of aortic pressure, lead II ECG, mean and pulsatile LCCA 
flow (Carolina Medical Electronics, Model 501 flowmeter, O-30 or O-100 ml/min 
range) and regional segment length were made on a Grass model 7 polygraph. Zero 
flow was determined by momentarily occluding the vessel distal to the flow probe 
and was confirmed during and upon termination of the experiment. The electromag- 
netic flow probe was calibrated initially using whole blood. 
LCCA stimulation and streptokinase infusion 
A fixed non-circumferential stenosis was produced at the point of electrode 
insertion in 22 of 35 preparations by adjustment of the screw occluder. This was a 
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TABLE 1 
Effect of a stenosis on LCCA occlusion and the success of streptokinase in recanalization. 





Saline (30 mm post 
occlusion; n = 5) 
Streptokinase (30 min 
post occlusion; n = 8) 
Stenosis 
Saline (30 min post 
occlusion; n = 5) 
Streptokinase (30 mitt 
post occlusion; n = 11) 
Streptokinase (90 min 
post occlusion; n = 6) 
27+4 211*26 O/5.0% 
28k2 214& 30 l/8,13’% 
30*3 67+13 * O/5,0% 
29+2 61+ 10 * g/11,73’% 
28*2 55+ 8* 5/6,83& 
- 
Mean LCCA flow prior to electrical stimulation and the time from the onset of stimulation until flow 
decreased to and remained at zero for 30 mm were compared among groups by one-way ANOVA and 
Duncan’s test. Means for groups with a stenosis were less (P < 0.05) than those for groups without a 
stenosis. The proportion of animals successfully recanalated are also provided for each group. 
relatively mild stenosis which resulted in an insignificant decrease in mean LCCA 
flow of 1.6 + 8.2% (~fr SD). It did, however, decrease diastolic flow by an average of 
19 + 4.5% (+ SD). 
Within 30 min after surgical preparation, a 100-PA d.c. current was applied to the 
intimal surface of the vessel and was continued until flow decreased to, and 
remained at, zero ml/mm for 30 min. Constant d.c. current was delivered from a 9 
V nickel-cadmium battery with the anode attached to the intracoronary electrode 
and the cathode placed in a subcutaneous site. Animals received a 50 ~l/rnin 
infusion of either 0.9% saline or STK (Hoechst-Roussel, 50 kU/2.5 ml saline at a 
rate of 1000 U/mm) over a 50-mitt period starting at either 30 or 90 min after the 
initiation of thrombotic occlusion as indicated in Table 1. In some instances, another 
50,000 U of STK was given at the end of the first infusion at twice the above rate for 
25 min. Upon completing the infusion(s), the heart was arrested with KC1 and the 
surgically isolated portion of the LCCA was clamped off proximally and distally and 
then removed. The isolated vessel segment was dissected logitudinally and any 
thrombus present at the site of injury was weighed immediately on an analytical 
balance. 
The direct effect of STK upon coronary flow was examined in 3 separate 
preparations where STK was infused at 1000 U/min for 50 min without a stimula- 
tion wire or stenosis present. 
Data calculations and statistical analyses 
Segment length was calculated at end-diastole (LVED length) and at end-systole 
(LVES length) as demarcated by the peak of the QRS complex and the dichrotic 
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notch on the aortic pressure curve, respectively. Percent segment shortening was 
calculated by the formula (LVED length-LVES length) + LVED length 100%. 
Equality of means between two groups was tested by the t-test. Multiple group 
comparisons were made by a one-factor or two-factor analysis of variance (ANOVA) 
with specific mean differences detected by Duncan’s test. A value of P -C 0.05, 
two-tailed, was considered significant. All values given in the text are expressed as 
mean + standard error of the mean (SEM). 
Results 
Effect of a stenosis on thrombogenesis and thrombolysis 
Flows prior to electrical stimulation were comparable among all treatment groups 
as indicated in Table 1. The predominate effects of the stenosis in these experiments 
were upon the time required for an occlusive thrombus to form and the ability of 
STK to establish reperfusion. The average time to occlusion was decreased 72% 
overall by the stenosis, suggesting that either a greater stimulus for thrombus 
formation was elicited or that the size of the thrombus required to completely 
obstruct the vessel was decreased. The latter possibility is supported by the data in 
Fig. 2, which shows that occlusive thrombi in saline-treated controls were on the 
average 40% smaller in the presence than in the absence of a stenosis. These control 
animals provided an estimate of thrombus mass present at the site of injury and 
demonstrated that once flow was decreased to zero over 30 min, spontaneous reflow 
did not occur over the next 2 hr. 
The number of animals from each treatment group which had measurable 
antegrade flow ( > 3 ml/mm) during STK infusion is also indicated in Table 1. 
Recanalization with STK was more effective with stenosed vessels and the resulting 
overall success rate of 76% was independent of whether infusion was begun 30 min 
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Fig. 2. Effect of a stenosis and streptokinase upon thrombus weight. Thrombi were isolated as described 
in Materials and Methods and weighed. Significant differences among the groups by one-way ANOVA 
were found with (+) less than control without stenosis at P < 0.05 and with (*) less than their respective 
controls at P i 0.05. Only one animal without a stenosis was reperfused; it had a thrombus weight of 17 
mt3. 
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or 90 min after thrombotic LCCA occlusion. Despite the relative inability of STK to 
induce reflow in animals lacking a stenosis, the average thrombus mass in these 
instances was diminished significantly by 30% relative to controls (Fig. 2). In 
STK-treated animals with a stenosis thrombus mass was reduced by 44% for the 
recanalized sub-group, while the non-reperfused sub-group failed to differ signifi- 
cantly from saline treated controls. Although reperfused vessels had smaller thrombi 
overall, residual thrombi weighing between 2-17 mg were observed in every instance 
at the termination of the infusion. 
Flow characteristics after recanalization 
Only one animal without a stenosis exhibited reflow and therefore flow-related 
data will be presented only from experiments where a stenosis was present. Fig. 3 
consists of sample recordings from an experiment where STK elicited reflow at 16 
min after the start of the infusion. This preparation was an exception in that 
pulsatile flow was restored; in all other cases the return of flow was non-pulsatile. 
Administering STK at 30 min compared to 90 min post-occlusion did not influence 
the reperfusion characteristics listed in Table 2 and, therefore, these data could be 
averaged together. 
The overall magnitude of the initial return of flow (14 + 1 ml/mm, n = 11) and 
the maximum flow during reperfusion (22 + 3 ml/mm, n = 11) were usually less 
THROMBOLYTIC ACTION OF STREPTOKINASE IN CORONARY ARTERY 
t t t t t t 
prestenosis stenosis 70 min 160 min 176 min 191 min 
0 min. 100 UA occlusion Streptokinase 
stimulate 1000 Wmin 
Fig. 3. Representative example of intracoronary streptokinase thrombolysis. The animal received 50,000 
U of streptokinase beginning 90 min after occlusion. Flow was reestablished after 16,000 U were delivered 
(176 min) and was comparable to pre-occlusive flow after 31,000 U (191 min). Reocclusion (not shown) 
occurred by 200 min. Mean LCCA flow, also recorded in this experiment, was unaffected by the stenosis. 
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TABLE 2 
Comparisons of reperfusion produced streptokinase infusions begun at 30 or 90 min post occlusion 
Time to streptokinase Time to reperfusion Initial flow upon Maximum flow 
infusion (min) Wn) reperfusion upon reperfusion 
ml/rnin % ml/min I 
Pre-occlusion Pre-occlusion 
30(n =ll) 22f3(n=8) 15*1 53f 8 22+3 76+13 
90(n=6) 28f7(n = 5) 13*3 48*11 21k3 70+10 
Data are provided from only the experiments where reflow was established, even if momentarily. 
Comparisons by the r-test demonstrated no significant differences between the two groups. 
than that existing prior to occlusion, indicating a lack of a reactive hyperemia. An 
overall average of 26 f 6 min (n = 11) of STK infusion (26,000 U) was required to 
initiate reperfusion, although a considerable range of 5 min to 50 min was obtained 
for this parameter. 
A very significant observation was the typical pattern of reflow which was 
obtained during STK infusion. The LCCA flows recorded during each successful 
reperfusion for animals receiving STK 30 min post-occlusion are summarized in Fig. 
4. Essentially identical results were obtained with the five recanalized preparations 
receiving STK at 90 mm post-occlusion. Flow was always unstable with sporadic 
fluctuations present during the entire period of STK infusion. Reocclusion of the 
vessel was observed in six of the eight preparations. To determine whether continued 
I 1 
0 10 20 30 40 50 
T STREPTOKINASE INFUSION (mid 
30 min post occlusion 
Fig. 4. Individual reperfusion patterns during streptokinase infusion. Changes in LCCA flow are 
presented for the 8 successfully reperfused animals in the group receiving streptokinase 30 min post 
occlusion. The maximum flows obtained over each 2-min period are plotted for each experiment as either 
a dotted or solid line for the sake of clarity. 
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or increased STK administration would be beneficial, three of these experiments 
were extended by infusing an additional 50,000 U STK over a 25min period. No 
appreciable improvement in flow was detected in these instances and the intermit- 
tent pattern continued. 
In the three experiments where STK was infused intracoronary in the absence of 
any thrombogenic stimuli (i.e., without electrical stimulation or stenosis), no effect 
on coronary flow was observed. Thus, STK itself was devoid of any significant 
coronary hemodynamic effect. 
Cardiac function during thrombogenesis and thrombolysis 
Sonomicrometer crystals were placed successfully in 24/35 of the animals in- 
cluded in the study. Representative changes in segmental shortening which occurred 
A-ALCCA t =wnent n + LAD smerrng 
A--ALCCA 
O---O LAD t LVED length 
(A) n=6 
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pestenosis s&or&is occlusion start reperfusion f&h 
, I I I 
stimulate 30 min streptokiiase 60 mid 
(B) n=4 
I 8 
prestenosis stFn& occlusion start reperfusion finish 
I I , -I 
stimulate 90 min streptokinase (50 mini 
Fig. 5. Changes in regional cardiac function during thrombosis and thrombolysis. Percent segmental 
shortening and percent increase in LVED length are shown for animals treated at 30 min (a) or 90 min (b) 
post occlusion. Data points which were found to be significantly different from the preceding measure- 
ments by two-way ANOVA are indicated by (*) P < 0.05 and (+ ) P -C 0.01. 
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in the LCCA and LAD perfusion beds upon thrombosis are shown in Fig. 3. 
Dyskinesis was evident when segmental length attained its greatest value at end-sys- 
tole rather than end-diastole; in these cases, percent segmental shortening was less 
than zero. There were a total of 3 animals (11%) which retained contractile function 
in the LCCA region upon thrombotic occlusion of the LCCA, suggesting an effective 
collateralization of the coronary circulation in these instances. 
The LV function data in Fig. 5 were derived from STK recanalized animals which 
demonstrated a loss of contraction in the LCCA region. Those animals receiving 
STK 30 min and 90 min post occlusion are shown separately; the corresponding 
times from occlusion until reflow began were 52 + 3 min and 118 f 7 min, respec- 
tively. None of the animals treated at the latter time point demonstrated any 
appreciable improvement in percent segmental shortening in the LCCA bed. STK 
infusion, at the earlier time, resulted in a small, but significant transient increase in 
segment shortening during the first few minutes of reperfusion. However, normal 
contractile function was not evident in this group since the average value was still 
less than zero. 
Only one animal (Fig. 3), demonstrated positive segment shortening of 6% upon 
reperfusion which compared to a value of 15% prior to occlusion. Contractile 
function did not change significantly in the LAD region during the course of the 
experiments for any treatment group. LVED length, which was increased upon 
occlusion, was not significantly affected by STK in either group. 
Discussion 
Reduction of thrombus mass and recanalization 
Streptokinase was relatively ineffective in reestablishing antegrade circumflex 
flow in the absencce of a fixed stenosis even though it significantly reduced 
thrombus mass compared to saline treatment. It is possible that the size of the 
thrombus existing before the initiation of thrombolytic therapy was a crucial factor 
in determining the ability of intracoronary STK to recanalize the vessel. This 
hypothesis is supported by both the reduction in occlusive thrombus mass obtained 
when the partial obstruction was placed at the site of injury in saline-treated animals 
and the observation that STK elicited a proportionately greater (45% vs. 30%) 
decrease in thrombus weight in the presence of a stenosis. Furthermore, the 
percentage of experiments where at least intermittent flow could be restored by 
infusing 50,000 U STK was increased from 13 to 76% by the stenosis. 
Despite its reduced size, a residual thrombus always was present at the site of 
electrode insertion whether or not flow was reestablished and no correlation was 
observed between the extent of reflow and the size of the remaining thrombus. 
Another interesting finding was the qualitative appearance of thrombi isolated from 
STK-treated animals which appeared to have a greater extent of red blood cell 
infiltration and were less firm than those removed from saline controls. 
In other animal studies where lesions have been induced in large coronary arteries 
by copper coils [6,7] or electrical current [8], antegrade flow during STK induced 
624 
reperfusion was not monitored continuously. However, coronary flow was recorded 
continuously by Karshi et al. [9] who described a canine model of thrombosis 
induced by thrombin where a high degree stenosis was present on the affected vessel. 
Intracoronary STK (100,000 U in 200 ml over 50 min) was capable of reestablishing 
flow in this preparation which, after 60 min of infusion, approximated that before 
occlusion. Although these investigators did not indicate whether reflow was sporadic 
or increased in a smooth manner, reperfusion was maintained for up to 2 hr after 
completion of the STK infusion. These results are in contrast to ours in which a 
lower maximum flow and dramatic oscillations in flow were observed during 
reperfusion. The disparity can be reconciled by postulating that the injection of 
thrombin [9,10] or autologous thrombi [ll] to produce occlusion may not inflict as 
severe a degree of injury to the vessel wall as does low intensity anodal current 
stimulation. 
Infusion of STK alone may be incapable of preventing continued adhesion and 
aggregation of platelets to a sufficiently severe lesion, a process which is likely to 
proceed even after thrombus disruption. The continuing accumulation and removal 
of platelets could provide for the release of large vessel constricting substances such 
as thromboxane or serotonin, thereby inducing or accentuating flow decreases. In 
fact, the combination of a localized intimal injury superimposed upon a narrowed 
lumen is an important characteristic of our model. This is relevant to the majority of 
recanalized infarct patients in whom a persistent partial obstruction is present, 
although in these instances, the vessel injury is atherosclerotic in nature [12-141. This 
physical deformation of the vessel may predispose to subsequent reocclusion which, 
although variable, has been reported to be as high as one-third of successful 
reperfusions [15,16]. 
Potential interventions during streptokinase tbrombolysis 
Meyer and co-workers [14] have suggested the use of balloon dilation in conjunc- 
tion with STK treatment when the organic material of the stenosis, which may 
consist of residual thrombi, is of a sufficiently soft consistency. However, the 
recognition of methods aimed at physically removing an obstruction must be 
tempered by the potential disadvantages to such techniques. For example, the use of 
a guide wire on STK-resistant vessels has been criticized because of frequent 
reocclusions [13,17] which may be increased by aggravation of the lesion. 
To achieve potentiation of thrombolysis and a greater success rate, some investi- 
gators have included plasmin (fibrinolysis) or plasminogen [6,7,18] with STK infu- 
sions. A synergistic action of plasminogen on STK has been demonstrated on 
thrombi in vitro 1191 although arguments against the effectiveness of this combined 
therapy in vivo have been presented [3]. Heparin has been reported to be an effective 
agent in preventing reocclusion [20] and our preliminary results indicate that 
coadministration of heparin can enhance the extent and persistence of STK induced 
reflow. Heparin did not eliminate reocclusion in these studies [21] although pros- 
tacyclin, a more effective antithrombotic agent, was beneficial in this regard. 
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Additional therapeutic interventions may be of advantage in limiting the injury of 
tissue resulting from the reperfusion process per se. Evidence for reperfusion injury 
in the clinical setting has been provided by Mathey et al. [22] who documented 
hemorrhagic infarcts upon necropsy in patients who were recanalized and in whom 
reflow was maintained until death. A number of recently developed experimental 
agents have been shown in animal models to increase the preservation of myocardium 
and to limit hemorrhagic infarction upon reperfusion without appreciably affecting 
cardiac oxygen supply or demand [23,24]. This type of intervention may become a 
logical extension of the therapeutic approach for the treatment of acute myocardial 
infarction. 
Myocardial function during thrombolysis 
The relative inability of STK to elicit a return of function when flow was restored 
after an average of 50 min (30 min STK group) to 110 min (90 min STK group) of 
occlusion is perhaps not surprising. According to previous studies 2-3 hr of ischemia 
requires l-2 weeks for return of segmental function [25] while after 90 min of 
ischemia, regional function remains depressed for up to 72 hr [26]. Conflicting 
results have been obtained with shorter periods of ischemia. Banka et al. [27] 
detected improved segmental function within 5 min of reperfusion after 30 or 45 
min, but not after 60 min, of occlusion. Kloner et al. [28] reported improved regional 
segment shortening within 1 to 60 min after 5 min, but not after ischemic periods of 
15 min or longer. Other data suggest that any immediate return of contractility after 
brief occlusions is short lived and quickly deteriorates [29]. 
We administered STK as soon as possible once the occlusion was established in 
the hope of obtaining even a transient increase in contractility in the ischemic 
region. Although our model differs from those employed by others in that the loss 
and return of flow are gradual processes, avoidance of rapid occlusion and reperfu- 
sion did not appear to facilitate any return of regional function. It is possible that 
the amount of flow repayment was inadequate for the return of contractility. 
Alternatively, some of the midwall myocardial tissue, where segmental length was 
being measured, may have been irreversibly injured. This is perhaps more likely in 
the group receiving STK at 60 min than at 30 min post occlusion [30]. Due to the 
acute nature of our preparation, histochemical or histological examination of infarc- 
tion was not accomplished. 
The clinical literature in part also supports the contention that return of regional 
cardiac function is a delayed event [31-331 requiring from days to weeks. However, 
there is some variability among investigators on this matter and both a lack of 
improvement in global function after reperfusion [34] and an immediate decrease in 
akinetic segment length upon reperfusion [35] have been described. It is likely that 
much of this variability may represent technical differences in the assessment of 
myocardial performance. Since global indices may mask important changes in 
regional function, improved methods of measuring contraction in selected locations 
should be given emphasis. 
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